Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831086 | 0.81 | TDP1 (0.46) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL3809049 | 0.79 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL1619697 | 0.79 | ALDH1A1 (0.42) | CYP3A4CYP2C9ALDH1A1HSD17B10HPGD | |
| SCHEMBL536216 | 0.76 | — | — | |
| SCHEMBL6476278 | 0.76 | TDP1 (0.48) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL11813018 | 0.76 | TDP1 (0.42) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL11853215 | 0.76 | TDP1 (0.42) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL11813032 | 0.76 | TDP1 (0.42) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL10062306 | 0.76 | TDP1 (0.42) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL9283778 | 0.75 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928222-B2 | Porphyrin compound, process for producing porphyrin compound, three-dimensional optical recording material, and three-dimensional optical recording medium | National University Corporation NARA Institute of Science and Technology (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20070224529-A1 | Porphyrin compound, process for producing porphyrin compound, three-dimensional optical recording material, and three-dimensional optical recording medium | National University Corporation NARA Institute of Science and Technology (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224529-A1 | Porphyrin compound, process for producing porphyrin compound, three-dimensional optical recording material, and three-dimensional optical recording medium | PPOX, PNMT, PAH | TDP1 1968/4885TSHR 3399/4885CYP3A4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.